MedTrace Logo

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

NCT06234423 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 263

Last updated 2026-01-14

No results posted yet for this study

Summary

This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

Conditions

Interventions

DRUG

CUSP06

Antibody drug conjugate (ADC)

Sponsors & Collaborators

  • OnCusp Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-09
Primary Completion
2027-05-30
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06234423 on ClinicalTrials.gov